Hommel Kevin A, Davis Christine M, Baldassano Robert N
Center for the Promotion of Treatment Adherence and Self-Management, Cincinnati, Ohio 45229-3039, USA.
Inflamm Bowel Dis. 2009 Apr;15(4):589-93. doi: 10.1002/ibd.20798.
The objective was to examine the prevalence and frequency of oral medication nonadherence using a multimethod assessment approach consisting of objective, subjective, and biological data in adolescents with inflammatory bowel disease (IBD).
Medication adherence was assessed via pill counts, patient/parent interview, and 6-thioguanine nucleotide (6-TGN)/6-methylmercaptopurine nucleotide (6-MMPN) metabolite bioassay in 42 adolescents with IBD. Pediatric gastroenterologists provided disease severity assessments.
The objective nonadherence prevalence was 64% for 6-MP/azathioprine (AZA) and 88% for 5-aminosalicylate (5-ASA) medications, whereas subjective nonadherence prevalence was 10% for 6-MP/AZA and 2% for 5-ASA. The objective nonadherence frequency was 38% for 6-MP/AZA and 49% for 5-ASA medications, and subjective nonadherence frequency was 6% for 6-MP/AZA and 3% for 5-ASA. The bioassay data revealed that only 14% of patients had therapeutic 6-TGN levels.
The results indicate that objectively measured medication nonadherence prevalence is consistent with that observed in other pediatric chronic illness populations, and that objective nonadherence frequency is considerable, with 40%-50% of doses missed by patients. Subjective assessments appeared to overestimate adherence. Bioassay adherence data, while compromised by pharmacokinetic variation, might be useful as a cursory screener for nonadherence with follow-up objective assessment. Nonadherence in 1 medication might also indicate nonadherence in other medications. Clinical implications and future research directions are provided.
目的是采用一种多方法评估方法,包括客观、主观和生物学数据,来检查炎症性肠病(IBD)青少年口服药物不依从的患病率和频率。
通过药丸计数、患者/家长访谈以及6-硫鸟嘌呤核苷酸(6-TGN)/6-甲基巯基嘌呤核苷酸(6-MMPN)代谢物生物测定法,对42例IBD青少年的药物依从性进行评估。儿科胃肠病学家提供疾病严重程度评估。
6-巯基嘌呤(6-MP)/硫唑嘌呤(AZA)的客观不依从患病率为64%,5-氨基水杨酸(5-ASA)药物为88%,而6-MP/AZA的主观不依从患病率为10%,5-ASA为2%。6-MP/AZA的客观不依从频率为38%,5-ASA药物为49%,主观不依从频率为6-MP/AZA为6%,5-ASA为3%。生物测定数据显示,只有14%的患者6-TGN水平处于治疗范围。
结果表明,客观测量的药物不依从患病率与其他儿科慢性病群体中观察到的一致,且客观不依从频率相当可观,患者错过40%-50%的剂量。主观评估似乎高估了依从性。生物测定依从性数据虽因药代动力学变异而受到影响,但作为不依从的初步筛查工具以及后续客观评估可能有用。一种药物的不依从也可能表明其他药物存在不依从情况。文中提供了临床意义和未来研究方向。